Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
11 03 2019
Historique:
received: 25 06 2018
accepted: 01 02 2019
entrez: 12 3 2019
pubmed: 12 3 2019
medline: 17 6 2020
Statut: epublish

Résumé

In tumors, extravascular fibrin forms provisional scaffolds for endothelial cell (EC) growth and motility during angiogenesis. We report that fibrin-mediated angiogenesis was inhibited and tumor growth delayed following postnatal deletion of Tgfbr2 in the endothelium of Cdh5-CreERT2 Tgfbr2fl/fl mice (Tgfbr2iECKO mice). ECs from Tgfbr2iECKO mice failed to upregulate the fibrinolysis inhibitor plasminogen activator inhibitor 1 (Serpine1, also known as PAI-1), due in part to uncoupled TGF-β-mediated suppression of miR-30c. Bypassing TGF-β signaling with vascular tropic nanoparticles that deliver miR-30c antagomiRs promoted PAI-1-dependent tumor growth and increased fibrin abundance, whereas miR-30c mimics inhibited tumor growth and promoted vascular-directed fibrinolysis in vivo. Using single-cell RNA-Seq and a NanoString miRNA array, we also found that subtypes of ECs in tumors showed spectrums of Serpine1 and miR-30c expression levels, suggesting functional diversity in ECs at the level of individual cells; indeed, fresh EC isolates from lung and mammary tumor models had differential abilities to degrade fibrin and launch new vessel sprouts, a finding that was linked to their inverse expression patterns of miR-30c and Serpine1 (i.e., miR-30chi Serpine1lo ECs were poorly angiogenic and miR-30clo Serpine1hi ECs were highly angiogenic). Thus, by balancing Serpine1 expression in ECs downstream of TGF-β, miR-30c functions as a tumor suppressor in the tumor microenvironment through its ability to promote fibrin degradation and inhibit blood vessel formation.

Identifiants

pubmed: 30855280
pii: 123106
doi: 10.1172/JCI123106
pmc: PMC6436861
doi:
pii:

Substances chimiques

MicroRNAs 0
Mirn30d microRNA, mouse 0
Neoplasm Proteins 0
Plasminogen Activator Inhibitor 1 0
RNA, Neoplasm 0
Transforming Growth Factor beta 0
Receptor, Transforming Growth Factor-beta Type II EC 2.7.11.30
Tgfbr2 protein, mouse EC 2.7.11.30

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1654-1670

Subventions

Organisme : NIEHS NIH HHS
ID : P30 ES010126
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126974
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA213793
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014051
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA044579
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177875
Pays : United States
Organisme : American Heart Association-American Stroke Association
ID : 15PRE24470053
Pays : United States

Références

J Clin Oncol. 2000 Feb;18(3):600-8
pubmed: 10653875
Blood Coagul Fibrinolysis. 2001 Jan;12(1):51-8
pubmed: 11229827
Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78
pubmed: 11252892
J Biol Chem. 2001 Sep 7;276(36):33964-8
pubmed: 11441025
Science. 2001 Aug 31;293(5535):1602-4
pubmed: 11533466
J Natl Cancer Inst. 2002 Jan 16;94(2):116-28
pubmed: 11792750
Blood. 2002 Jul 15;100(2):560-8
pubmed: 12091349
Cancer Res. 2002 Dec 1;62(23):6966-72
pubmed: 12460914
Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43
pubmed: 12461559
Am J Pathol. 2003 Jun;162(6):1747-57
pubmed: 12759232
Nat Struct Biol. 2003 Jul;10(7):541-4
pubmed: 12808446
Cell. 2003 Jun 13;113(6):685-700
pubmed: 12809600
Blood. 2003 Oct 15;102(8):2819-27
pubmed: 12829586
Oncogene. 2003 Jul 10;22(28):4389-97
pubmed: 12853975
Microvasc Res. 2003 Sep;66(2):102-12
pubmed: 12935768
Science. 2004 Feb 6;303(5659):848-51
pubmed: 14764882
Nat Rev Cancer. 2005 Aug;5(8):591-602
pubmed: 16056258
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Cell. 2007 Jun;11(6):539-54
pubmed: 17560335
Annu Rev Pathol. 2007;2:251-75
pubmed: 18039100
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
Nat Rev Mol Cell Biol. 2008 Aug;9(8):628-38
pubmed: 18628784
Cancer Cell. 2008 Sep 9;14(3):201-11
pubmed: 18772110
Cancer Cell. 2008 Oct 7;14(4):324-34
pubmed: 18835034
Circ Res. 2009 Jan 30;104(2):170-8, 6p following 178
pubmed: 19096030
Nat Med. 2009 Jan;15(1):68-74
pubmed: 19122658
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
Curr Opin Genet Dev. 2009 Jun;19(3):205-11
pubmed: 19446450
PLoS Genet. 2010 Jan;6(1):e1000795
pubmed: 20062521
Blood. 2010 Nov 11;116(19):4025-33
pubmed: 20705756
Biochem J. 2011 Mar 15;434(3):473-82
pubmed: 21175428
Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006544
pubmed: 22355795
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006536
pubmed: 22393533
Breast Cancer Res. 2012 Aug 20;14(4):R120
pubmed: 22906178
PLoS One. 2012;7(8):e44532
pubmed: 22952991
J Natl Cancer Inst. 2012 Oct 3;104(19):1470-84
pubmed: 22984202
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30
pubmed: 22992590
Blood. 2012 Dec 13;120(25):5063-72
pubmed: 23086751
EMBO J. 2013 Jan 23;32(2):219-30
pubmed: 23188081
Breast Cancer Res Treat. 2013 Jan;137(2):373-82
pubmed: 23224145
Nat Commun. 2013;4:1393
pubmed: 23340433
Nat Cell Biol. 2013 Jul;15(7):807-17
pubmed: 23728425
Cell. 1990 Aug 10;62(3):435-45
pubmed: 2379237
Clin Cancer Res. 2013 Aug 15;19(16):4477-87
pubmed: 23797906
Hypertension. 2013 Sep;62(3):592-8
pubmed: 23817492
Mol Cancer Ther. 2013 Nov;12(11):2378-88
pubmed: 23990114
J Am Soc Nephrol. 2014 Jan;25(1):92-104
pubmed: 24029422
Mol Cancer Ther. 2013 Dec;12(12):2697-708
pubmed: 24072883
Angiogenesis. 2014 Jul;17(3):511-8
pubmed: 24257808
Cell. 2014 Feb 27;156(5):1002-16
pubmed: 24581498
Am Rev Respir Dis. 1989 Oct;140(4):1104-7
pubmed: 2478057
Nat Nanotechnol. 2014 Aug;9(8):648-655
pubmed: 24813696
Trends Genet. 2014 Jul;30(7):298-307
pubmed: 24929628
Nat Med. 2014 Jul;20(7):741-7
pubmed: 24929950
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3553-61
pubmed: 25114235
Cancer Biol Ther. 2015;16(2):253-60
pubmed: 25587663
Cancer Res. 2015 Apr 1;75(7):1244-54
pubmed: 25634211
Breast Cancer Res. 2014 Aug 22;16(4):428
pubmed: 25677449
Cancer Res. 2015 Aug 1;75(15):2969-74
pubmed: 26180080
PLoS One. 2015 Jul 24;10(7):e0133786
pubmed: 26207899
Nat Commun. 2015 Aug 12;6:7984
pubmed: 26264658
J Vis Exp. 2015 Oct 14;(105):e53072
pubmed: 26554446
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Res. 2016 Jun 1;76(11):3285-94
pubmed: 27197170
Sci Rep. 2016 Nov 07;6:36687
pubmed: 27819307
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):492-497
pubmed: 28034921
PLoS One. 2017 Oct 4;12(10):e0185619
pubmed: 28977001
Nat Methods. 2018 Apr;15(4):255-261
pubmed: 29481549
Nat Commun. 2018 Aug 7;9(1):3119
pubmed: 30087332
Am J Pathol. 1988 Mar;130(3):455-65
pubmed: 3279791
N Engl J Med. 1986 Dec 25;315(26):1650-9
pubmed: 3537791
J Natl Cancer Inst. 1981 Aug;67(2):335-45
pubmed: 6267343
Blood. 1994 Jun 1;83(11):3206-17
pubmed: 7514904
Exp Cell Res. 1993 Feb;204(2):356-63
pubmed: 7679998
Blood. 1996 Jun 1;87(11):4718-22
pubmed: 8639841
Cytokine Growth Factor Rev. 1997 Mar;8(1):21-43
pubmed: 9174661
EMBO J. 1998 Jun 1;17(11):3091-100
pubmed: 9606191
Nat Med. 1998 Aug;4(8):923-8
pubmed: 9701244

Auteurs

James V McCann (JV)

Department of Cell Biology and Physiology, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, North Carolina, USA.

Lin Xiao (L)

Children's Cancer Institute, Kensington, New South Wales, Australia.

Dae Joong Kim (DJ)

Department of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, Virginia, USA.

Omar F Khan (OF)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT).
Department of Chemical Engineering.

Piotr S Kowalski (PS)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT).

Daniel G Anderson (DG)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT).
Department of Chemical Engineering.
Harvard-MIT Division of Health Sciences and Technology, and.
Institute for Medical Engineering and Science, MIT, Cambridge, Massachusetts, USA.

Chad V Pecot (CV)

Lineberger Comprehensive Cancer Center.
School of Medicine.

Salma H Azam (SH)

Department of Genetics, and.

Joel S Parker (JS)

Lineberger Comprehensive Cancer Center.
School of Medicine.
Department of Genetics, and.

Yihsuan S Tsai (YS)

Lineberger Comprehensive Cancer Center.

Alisa S Wolberg (AS)

Department of Pathology and Laboratory Medicine, UNC McAllister Heart Institute, UNC at Chapel Hill, Chapel Hill, North Carolina, USA.

Stephen D Turner (SD)

Department of Public Health Sciences, and.
Bioinformatics Core, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Kohei Tatsumi (K)

Department of Medicine, Division of Hematology and Oncology, UNC McAllister Heart Institute, UNC at Chapel Hill, Chapel Hill, North Carolina, USA.

Nigel Mackman (N)

Department of Medicine, Division of Hematology and Oncology, UNC McAllister Heart Institute, UNC at Chapel Hill, Chapel Hill, North Carolina, USA.

Andrew C Dudley (AC)

Department of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, Virginia, USA.
Emily Couric Cancer Center, The University of Virginia, Charlottesville, Virginia, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH